- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01651156
Efficacy and Safety Study of Tolvaptan to Treat Patients With Cardiac Edema
Randomized, Double-blind, Multicenter, Placebo-controlled, Parallel Phase 3 Study to Evaluate the Efficacy and Safety of Tolvaptan in the Treatment of Patients With Cardiac Edema Based on the Conventional Therapy
A randomized, double-blind, multicenter, placebo-controlled, parallel study to evaluate the efficacy and safety of Tolvaptan in the treatment of patients with cardiac edema (body fluid retention caused by congestive heart failure) based on the conventional therapy.
To evaluate the efficacy and safety of Tolvaptan 15 mg on congestive heart failure patients with body fluid retention after current diuretic treatment, after continuous treatment of 7 days' oral Tolvaptan 15mg or placebo.
Study Overview
Detailed Description
- A randomized, double-blind, multicenter, placebo-controlled, parallel study
- Study population: The congestive heart failure patients with body fluid retention after received current diuretics therapy
- Number of patients: Patients will be randomly assigned to Tolvaptan and placebo group in 1:1 ratio, 120 patients in each group, 240 patients in total
- Group assignment method: Tolvaptan 15 mg group: conventional therapy + Tolvaptan 15 mg Placebo group: conventional therapy + placebo
- Administration and dosage of the study drug: Once daily, 1 tablet be taken orally after breakfast, for successive 7 days
- Study period:
- Screening period (4 days in minimum, 7 days in maximum), including:
Screening period: from the time the informed consent form is signed to Day -4 Observation period: 3 days before drug administration
- Treatment period: 7 days
- Follow up visits: Day 8 (efficacy evaluation day) and Day 7 (+3) after the last dosing
- Post treatment survey: Day 14 (+3) after the last dosing
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310013
- Zhejiang Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Patients treated with one of the oral diuretic therapy standards (include the patients who will be treated with one of the oral diuretic therapy standards from the beginning of the observation period):
- Only 40 mg/day furosemide taken orally or other oral loop diuretics equivalent to 40 mg/day furosemide note 1)
- Combination treatment of oral loop diuretics and thiazide diuretics (no dosage limitation)
- Combination treatment of oral loop diuretics and aldosterone antagonists (no dosage limitation)
- Because of the existence of excess body fluid retention, the congestive heart failure patient has at least one of these symptoms (the lower extremity edema, pulmonary congestion note 2), or jugular vein engorgement).
- 20-85 years of age (inclusive) at the time of signing the informed consent document.
- Gender: male or female.
- Inpatients or patient who would be hospitalized from one day before the observation period to the end of efficacy evaluation examination after the last dosing (from Day -4 to the end of efficacy evaluation examination after the last dosing).
- Patient who have signed the informed consent form.
Exclusion Criteria:
- Patients equipped with circulatory assistant device.
Patients with any of following diseases, complications or symptoms:
- Suspected decreased blood volume
- Obstructive hypertrophic cardiomyopathy
- Severe aortic stenosis
- Hepatic coma
- Patients with history of acute myocardial infarction within 30 days prior to screening.
- Patients with diagnosed active myocarditis or amyloid cardiomyopathy.
Patients with the following diseases, complications or symptoms:
- Poorly controlled diabetes with a fasting glucose more than 220 mg/dL (or 12.21 mmol/L)
- Anuria
- Dysuria caused by urethral stricture, calculus or tumor
Patients with the following medical history of:
- Sustained ventricular tachycardia or ventricular fibrillation within 30 days prior to screening
- History of cerebrovascular accident within the past 30 days
- Past allergy or hypersensitive reactions to benzodiazepines (e.g. mozavaptan hydrochloride or benazepril hydrochloride)
- Obese patients whose body mass index (BMI = body weight (kg) / height (m)2 ) is more than 35.
- Patients with systolic pressure below 90 mmHg in supine position.
Patients with any of the following abnormal laboratory test parameters:
- Total bilirubin > 2.5 times the upper limits of normal value
- Serum creatine > 2.5 times the upper limits of normal value
- Serum Na+ > 145 mmol/L (or higher than the upper limits of normal value)
- Serum K+ > 5.5 mmol/L
- Patients who unable to take medicine orally.
- Female patients who are pregnant, breast-feeding, at childbearing ages, or with pregnancy plan.
- Patients who participated in clinical trials of other medicine and took other study drugs within 30 days prior to sign the informed consent form.
- Patients who participated in the clinical trial of Tolvaptan and took Tolvaptan previously.
- Patients who have received approved Tolvaptan tablets (Trade name: Samsca) previously.
- Except for the above, patients who were unsuitable to participate in this trial in the investigator's opinion.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: placebo
Frequency: once per day Duration: 7days
|
|
Experimental: Tolvaptan
Tolvaptan tablet Frequency: once per day Duration: 7days
|
oral taken
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
body weight (change from baseline)
Time Frame: screening day, Day-3, Day-2, Day-1, Day1, Day2, Day3, Day4, Day5, Day6, Day7, Day8, Day(7+3)
|
screening day, Day-3, Day-2, Day-1, Day1, Day2, Day3, Day4, Day5, Day6, Day7, Day8, Day(7+3)
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Body weight (percent change from baseline)
Time Frame: screening day, Day-3, Day-2, Day-1, Day1, Day2, Day3, Day4, Day5, Day6, Day7, Day8, Day(7+3)
|
screening day, Day-3, Day-2, Day-1, Day1, Day2, Day3, Day4, Day5, Day6, Day7, Day8, Day(7+3)
|
Collaborators and Investigators
Investigators
- Principal Investigator: Zhang Jian, Fuwai Cardiovascular Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 156-12-809-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiac Edema
-
Otsuka Pharmaceutical Co., Ltd.RecruitingCardiac Edema (CHF)Japan
-
Taiwan Otsuka Pharm. Co., LtdCompletedCardiac-induced EdemaTaiwan
-
Otsuka Pharmaceutical Co., Ltd.Completed
-
Otsuka Pharmaceutical Co., Ltd.Completed
-
Biobeat Technologies Ltd.CompletedAcute Cardiac Event | Acute Cardiac Failure | Acute Cardiac Pulmonary EdemaIsrael
-
Emergency Medical Service of the Central Bohemian...Masaryk Hospital Usti nad Labem; Institute of Experimental Physics, Slovak...Completed
-
Otsuka Pharmaceutical Co., Ltd.Completed
-
Fondazione Policlinico Universitario Agostino Gemelli...Active, not recruiting
-
Indiana UniversityVanderbilt UniversityTerminatedHeart Failure | Acute Cardiac Failure | Acute Cardiac Pulmonary Edema | Heart Failure AcuteUnited States
-
Indiana UniversityWayne State University; Vanderbilt University; Case Western Reserve University; Inova Fairfax HospitalCompletedHeart Failure | Acute Cardiac Failure | Acute Cardiac Pulmonary Edema | Heart Failure AcuteUnited States
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States